USFDA Classifies Cipla's Goa Facility Inspection as Voluntary Action Indicated (VAI)
Cipla Ltd has received the classification from the United States Food and Drug Administration (USFDA) regarding the routine Good Manufacturing Practices (cGMP) inspection conducted at its manufacturing facility in Verna, Goa. The USFDA classified the inspection as Voluntary Action Indicated (VAI).The investigation covered both the routine cGMP inspection and a Pre-Approval Inspection (PAI) at the company's facility located in Verna, Goa, India. These inspections took place between April 6 and April 17, 2026. The USFDA issued its classification via communication dated June 10, 2026.CIPLA Stock Price Movement
Shares of Cipla Limited are edging higher...